Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067413) USE OF FENFLURAMINE FORMULATION IN REDUCING NUMBER AND FREQUENCIES OF CONVULSIVE SEIZURES IN PATIENT POPULATIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067413 International Application No.: PCT/US2018/052580
Publication Date: 04.04.2019 International Filing Date: 25.09.2018
IPC:
A61K 31/137 (2006.01) ,A61P 25/08 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
137
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
08
Antiepileptics; Anticonvulsants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
FARFEL, Gail [US/US]; US
LOCK, Michael [US/US]; US
GALER, Bradley S. [US/US]; US
MORRISON, Glenn [CA/US]; US
BOYD, Brooks M. [US/US]; US
ZOGENIX INTERNATIONAL LIMITED [GB/GB]; Siena Court Broadway Maidenhead Berkshire SL6 1NJ, GB
Inventors:
FARFEL, Gail; US
LOCK, Michael; US
GALER, Bradley S.; US
MORRISON, Glenn; US
BOYD, Brooks M.; US
Agent:
BOZICEVIC, Karl; US
Priority Data:
16/139,60824.09.2018US
16/139,61724.09.2018US
16/139,69824.09.2018US
16/139,70124.09.2018US
16/139,70424.09.2018US
16/139,76324.09.2018US
62/563,25526.09.2017US
62/564,22527.09.2017US
62/579,45031.10.2017US
62/593,02930.11.2017US
62/627,32907.02.2018US
62/669,83310.05.2018US
62/696,80111.07.2018US
Title (EN) USE OF FENFLURAMINE FORMULATION IN REDUCING NUMBER AND FREQUENCIES OF CONVULSIVE SEIZURES IN PATIENT POPULATIONS
(FR) UTILISATION D'UNE FORMULATION DE FENFLURAMINE POUR RÉDUIRE LE NOMBRE ET LES FRÉQUENCES DE CRISES CONVULSIVES DANS DES POPULATIONS DE PATIENTS
Abstract:
(EN) A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.
(FR) L'invention concerne une méthode de réduction de la fréquence de crises convulsives chez un patient humain chez qui on a diagnostiqué le syndrome de Dravet, consistant à administrer au patient une dose thérapeutiquement efficace de fenfluramine ou d'un sel, d'une base, d'un acide ou d'une amine pharmaceutiquement acceptable de celle-ci, et à répéter l'administration pendant une période de jours jusqu'à ce que le patient présente une réduction significative (par exemple, au moins 40 %) par rapport à la ligne de base de la fréquence de crises convulsives. Dans certains modes de réalisation de la méthode, les crises convulsives sont complètement éliminées pendant au moins 10 jours, au moins 20 jours, au moins 30 jours, au moins 50 jours, au moins 100 jours.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)